Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Great Point Partners and Kura Oncology Inc (KURA)

Page 1 of 10

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Great Point Partners 0 1,638,461 0 1,638,461 1,638,461 5.92%
Dr. Jeffrey R. Jay, M.D 0 1,638,461 0 1,638,461 1,638,461 5.92%
Mr. David Kroin 0 1,638,461 0 1,638,461 1,638,461 5.92%
Jeffrey Jay And David Kroin
Jeffrey Jay And David Kroin
Great Point Partners

Page 1 of 10 – SEC Filing

Washington, D.C. 20549


Schedule 13G


Under the Securities Exchange
Act of 1934

(Amendment No. )*


Oncology, Inc.

(Name of Issuer)


(Title of Class of Securities)


(CUSIP Number)

11, 2017

(Date of Event which Requires
Filing of this Statement)

Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)

*The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in
the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Persons who respond to the
collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Follow Kura Oncology Inc.
Trade (KURA) Now!
Page 1 of 10